Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Norway
  4. Oslo Bors
  5. BerGenBio ASA
  6. Summary
    BGBIO   NO0010650013

BERGENBIO ASA

(BGBIO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Oslo Bors
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
18.82(c) 18.67(c) 18.5(c) 18.04(c) 18.02(c) Last
96 606 74 338 126 058 141 656 111 963 Volume
-0.21% -0.80% -0.91% -2.49% -0.11% Change
More quotes
Estimated financial data (e)
Sales 2021 - - -
Net income 2021 -309 M -33,7 M -33,7 M
Net cash position 2021 402 M 43,8 M 43,8 M
P/E ratio 2021 -5,13x
Yield 2021 -
Sales 2022 233 M 25,3 M 25,3 M
Net income 2022 -228 M -24,9 M -24,9 M
Net cash position 2022 210 M 22,9 M 22,9 M
P/E ratio 2022 -7,05x
Yield 2022 -
Capitalization 1 594 M 174 M 174 M
EV / Sales 2021 -
EV / Sales 2022 5,95x
Nbr of Employees 46
Free-Float 57,5%
More Financials
Company
Bergenbio ASA is Norway-based company that provides technology platforms used in the research and pre-clinical development of drug targets, associated biomarkers and therapeutics for the treatment of cancer. The Company's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) kinase inhibitors, small molecule AXL inhibitors, and antibody programs. Its flagship product... 
More about the company
Ratings of BerGenBio ASA
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about BERGENBIO ASA
11/17BERGENBIO ASA : Share capital increase
AQ
11/16Bergenbio asa - results for the third quarter of 2021
AQ
11/16BerGenBio ASA Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
11/16BERGENBIO ASA : Results for the third quarter of 2021
AQ
11/09BERGENBIO ASA : Increase of share capital, exercise of share options
AQ
11/09BERGENBIO RECEIVES FDA FAST TRACK DESIGNATION FOR BEMCENTINIB in STK11-mutated advanced..
PU
11/09BerGenBio ASA Presents Pre-Clinical and Clinical Data on Bemcentinib in STK11-Positive ..
CI
11/09Bergenbio receives fda fast track designation for bemcentinib inástk11-mutated advanced..
AQ
11/09Bergenbio presents pre-clinical and clinical data onábemcentinib in stk11-positive nscl..
AQ
11/04Bergenbio to present updated bemcentinibáaml data atáash 2021 meeting
AQ
11/04BERGENBIO ASA : Invitation to third quarter 2021 results presentation and webcast
AQ
10/04BERGENBIO ASA : Share capital increase
AQ
10/01BERGENBIO : Announces poster presentation at society for immunotherapy of cancerá(sitc) an..
AQ
09/30BERGENBIO ASA : Increase of share capital, exercise of share options
AQ
09/30BERGENBIO ASA : Increase of share capital, exercise of share options
AQ
More news
News in other languages on BERGENBIO ASA
09/08BerGenBio recrute 86 patients pour un essai de phase II sur un médicament contre la leu..
08/24BerGenBio nomme le président d'AcouSort au poste de PDG
08/23Le PDG de Bergenbio démissionne, son successeur est nommé
08/06BerGenBio nomme un responsable intérimaire du développement clinique, le médecin-chef q..
06/29Le médicament COVID-19 de Bergenbio réduit le nombre de décès dans les études de stade ..
More news
Chart BERGENBIO ASA
Duration : Period :
BerGenBio ASA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BERGENBIO ASA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 18,02 NOK
Average target price 53,67 NOK
Spread / Average Target 198%
EPS Revisions
Managers and Directors
Martin Olin Chief Executive Officer
Rune Skeie Chief Financial Officer
Sveinung Hole Chairman
Alison Messom Director-Clinical Operations
E. Gwyn Thomas Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
BERGENBIO ASA-43.98%174
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.23%66 409
WUXI APPTEC CO., LTD.26.31%65 758
VERTEX PHARMACEUTICALS-13.76%51 819